Skip to content

DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.

Registry of Patients Included in the DEPRECAP (Lung Cancer Screening Porgramme by Low-dose Computed Tomography for Patients With Chronic Obstructive Pulmonary Disease (COPD) or Emphysema.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06690385
Acronym
DEPRECAP
Enrollment
1998
Registered
2024-11-15
Start date
2014-01-14
Completion date
2024-11-13
Last updated
2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Emphysema, Lung Cancer

Keywords

Lung cancer screening, Low-dose computed CT, COPD, Emphysema

Brief summary

The DEPRECAP (Early detection of lung cancer) study is an ongoing, prospective, longitudinal, multicenter lung cancer screening program that recruited individuals with COPD or emphysema from the pulmonary clinics of Fundación Jiménez Díaz University Hospital and Villalba General Hospital, in Madrid, Spain. The aim of this observational study is to determine the scientific evidence needed to study the benefit and potential effects of lung cancer screening in this group of patients and to determine the long-term effects of the intervention in reducing the high mortality rates associated with late-stage lung cancer diagnosis in a very high-risk population, to address under-diagnosis of COPD and to promote smoking cessation. This leads to the creation of a registry with clinical, radiological, functional data and biological samples for future studies in this cohort of patients to provide the scientific evidence needed to study the benefit and potential effects of screening for lung cancer and other tobacco-related pathologies diagnosed by Low-dose CT (LDCT)

Detailed description

Participants who met the inclusion/exclusion criteria detailed below and agreed to participate, underwent annual LDCT and pulmonary function tests until age 75 or 15 years of smoking abstinence, whichever came first. The study protocol was approved by the Ethics Committee of the Fundación Jiménez Díaz (ER2\_EO180-19\_FJD-HGV) and all participants signed their informed consent. Inclusion criteria were males or females, 55-75 years of age, current or former smokers (Less than 15 years of abstinence) with a cumulative smoking exposure of greather than 30 pack-years and a diagnosis of COPD according to the GOLD guidelines and/or emphysema identified by LDCT. Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded.

Interventions

None listed

Sponsors

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Current or former smokers (\>15 years of abstinence) with a cumulative smoking exposure of \> 30 pack-years * Diagnosis of COPD according to the GOLD guidelines and/or emphysema identified by LDCT and/or a carbon monoxide diffusing capacity (DLCO) lower than 80% of predicted (as per the Global Lung Function Initiative (GLI) equations)

Exclusion criteria

* Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Lung cancer screening15 yearsCreation of a multi-centre pilot lung cancer screening programme targeting high-risk subjects. with COPD and emphysema.

Secondary

MeasureTime frameDescription
Lung cancer screening15 yearsTo create a multicenter registry of clinical data, radiological images and blood samples to provide scientific evidence to study the benefit of lung cancer screening in patients with COPD or emphysema.
Lung cancer screening: smoking cessation15 yearsTo determine the effect of primary and secondary prevention on smoking cessation as a key element in the follow-up of the patients included.

Other

MeasureTime frameDescription
Lung cancer screening: comorbidities associated15 yearsUse follow-up in the screening programme to diagnose high-impact comorbidities associated with smoking such as COPD, pulmonary emphysema, bronchiectasis, incipient interstitial lung disease (ILA) or established interstitial lung disease and coronary heart disease.

Countries

Spain

Contacts

Primary ContactCarolina Gotera, MD
carolina.gotera@fjd.es+34 915504800
Backup ContactMaría Jesús Rodríguez Nieto, MD phD
mjrodriguezn@fjd.es+34 915504800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026